Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 17/20 | 0.62 |
| ▸ | ESRRB | O95718 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESRRG | P62508 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | VHL | P40337 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648909 | 1.00 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650091 | 1.00 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL651256 | 1.00 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648125 | 0.99 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648126 | 0.99 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL649119 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL649120 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650136 | 0.93 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650137 | 0.93 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4405009 | 0.90 | ESRRA (0.49) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | claimed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | claimed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20240050363-A1 | VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI YONSUN BIOTECHNOLOGY CO., LTD. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-4268802-A1 | VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Yonsun Biotechnology Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022135343-A1 | VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海博志研新药物技术有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-03 | — | — | US | disclosed |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | DR. REDDY'S LABORATORIES LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| WO-2016128987-A1 | A PROCESS FOR PREPARATION OF 2-BENZOFURANCARBOXAMIDE, 5-[4-[4-(5CYANO-1H-INDOL-3-YL)BUTYL]-1-PIPERAZINYL] FREE BASE AND ITS HYDROCHLORIDE SALT | HARMAN FINOCHEM LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128987-A1 | A PROCESS FOR PREPARATION OF 2-BENZOFURANCARBOXAMIDE, 5-[4-[4-(5CYANO-1H-INDOL-3-YL)BUTYL]-1-PIPERAZINYL] FREE BASE AND ITS HYDROCHLORIDE SALT | HARMAN FINOCHEM LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109737-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109731-A2 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JASSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050363-A1 | VILAZODONE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | VPS51, VARS1, VMA21 | ESRRA 1402/4885ESRRB 2764/4885ESR1 2434/4885 |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | ESRRA 2809/4885ESRRB 3586/4885ESR1 3291/4885 |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | VIL1, VMA21, PYGL | ESRRA 2809/4885ESRRB 3586/4885ESR1 3291/4885 |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | ESRRA 2809/4885ESRRB 3586/4885ESR1 3291/4885 |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.